TCON (TRACON Pharmaceuticals) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TRACON Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TRACON Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for TRACON Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

TCON' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.74 Med: 6.02 Max: No Debt
Current: 26.57

During the past 12 years, TRACON Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.74. And the median was 6.02.

TCON's Cash-to-Debt is ranked better than
65.97% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs TCON: 26.57

TRACON Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for TRACON Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

TRACON Pharmaceuticals Cash-to-Debt Chart

TRACON Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.88

7.98

15.65

1.74

36.29

TRACON Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	36.29	No Debt	No Debt

Competitive Comparison of TRACON Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, TRACON Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TRACON Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Cash-to-Debt falls into.

TRACON Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

TRACON Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.564	/	(0.236	+	0)
	=	36.29

TRACON Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

TRACON Pharmaceuticals had no debt ⁽¹⁾.

TRACON Pharmaceuticals (OTCPK:TCON) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

TRACON Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TRACON Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122

Website

https://www.traconpharma.com

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer	director, officer: President and CEO	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams	officer: Chief Operating Officer	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown	officer: Chief Accounting Officer (PAO)	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue	director	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins	officer: Chief Business Officer	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani	10 percent owner, other: Member of 10% Group	12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc	10 percent owner	950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022